Does Rallies show Form 4 insider transactions for UTHR?

Yes. Rallies tracks UTHR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is UTHR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for UTHR. It does not provide personalized investment advice.

UTHR (United Therapeutics) Stock Analysis - Insider Trades

United Therapeutics (UTHR) is a publicly traded Healthcare sector company. As of May 21, 2026, UTHR trades at $562.26 with a market cap of $24.07B and a P/E ratio of 19.26. UTHR moved -0.44% today. Year to date, UTHR is +15.16%; over the trailing twelve months it is +82.17%. Its 52-week range spans $266.98 to $609.35. Analyst consensus is strong buy with an average price target of $647.83. Rallies surfaces UTHR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading UTHR stock inside the company?

Recent UTHR insider activity includes ROTHBLATT MARTINE A sold 1.48K, ROTHBLATT MARTINE A sold 1.87K, ROTHBLATT MARTINE A sold 3.21K, ROTHBLATT MARTINE A sold 1.68K, and ROTHBLATT MARTINE A sold 616. Rallies tracks insider transaction dates, shares, prices, and estimated values.

UTHR Key Metrics

Key financial metrics for UTHR
Metric	Value
Price	$562.26
Market Cap	$24.07B
P/E Ratio	19.26
EPS	$29.27
Dividend Yield	0.00%
52-Week High	$609.35
52-Week Low	$266.98
Volume	42
Avg Volume	0
Revenue (TTM)	$3.17B
Net Income	$1.29B
Gross Margin	86.58%

Recent UTHR Insider Trades

ROTHBLATT MARTINE A sold 1.48K (~$836.26K) on May 15, 2026.
ROTHBLATT MARTINE A sold 1.87K (~$1.06M) on May 15, 2026.
ROTHBLATT MARTINE A sold 3.21K (~$1.82M) on May 15, 2026.
ROTHBLATT MARTINE A sold 1.68K (~$957.10K) on May 15, 2026.
ROTHBLATT MARTINE A sold 616 (~$351.08K) on May 15, 2026.

Latest UTHR News

United Therapeutics slides despite same-day Wells Fargo upgrade after Q1 results digestion — May 7, 2026
United Therapeutics jumps as Q1 results spotlight ralinepag DPI plans and trial momentum — May 6, 2026
United Therapeutics rises as ralinepag Phase 3 win and $2B buyback support shares — Apr 8, 2026
United Therapeutics falls as traders lock in gains after TETON-1-driven surge — Apr 2, 2026
United Therapeutics dips 3% as investors lock in gains after March catalysts — Apr 1, 2026

UTHR Analyst Consensus

13 analysts cover UTHR: 0 strong buy, 10 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $647.83.

Common questions about UTHR

Who is trading UTHR stock inside the company?: Recent UTHR insider activity includes ROTHBLATT MARTINE A sold 1.48K, ROTHBLATT MARTINE A sold 1.87K, ROTHBLATT MARTINE A sold 3.21K, ROTHBLATT MARTINE A sold 1.68K, and ROTHBLATT MARTINE A sold 616. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for UTHR?: Yes. Rallies tracks UTHR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is UTHR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for UTHR. It does not provide personalized investment advice.